

## Advances in the management of mCRC: current trends and future perspectives

Friday 5 July 2019, 13.10–14.40

## **Programme**

Welcome and introduction

Hans Prenen, Belgium

Optimising 1<sup>st</sup>-line treatment strategies for *RAS* WT mCRC

Dominik Modest, Germany

Oncolytic immunotherapy: a new treatment option for patients with liver metastases?

Markus Möhler, Germany

**Closing remarks** 

Hans Prenen, Belgium



Oncology

Amgen (Europe) GmbH 6343 Rotkreuz, Switzerland Date of preparation: March 2019 www.amgen.com © 2019 Amgen Inc. All rights reserved.